Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.5178 USD | +2.94% | +1.23% | -4.69% |
Mar. 22 | Sangamo Therapeutics Prices $24 Million Registered Direct Offering | MT |
Mar. 14 | Sangamo Therapeutics Pushes Neurology Programs Toward Clinical Development, Wedbush Says | MT |
Business Summary
Number of employees: 405
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Zinc Finger Protein
100.0
%
| 111 | 100.0 % | 176 | 100.0 % | +58.34% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 111 | 100.0 % | 176 | 100.0 % | +58.34% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Alexander Macrae
CEO | Chief Executive Officer | 61 | 16-05-31 |
Director of Finance/CFO | 46 | 19-02-28 | |
Gregory Davis
CTO | Chief Tech/Sci/R&D Officer | - | 20-04-30 |
Phillip Ramsey
CTO | Chief Tech/Sci/R&D Officer | - | - |
Louise Wilkie
IRC | Investor Relations Contact | - | 20-08-31 |
Amy Pooler
PRN | Corporate Officer/Principal | - | - |
Corporate Officer/Principal | - | 19-08-31 | |
Scott Willoughby
LAW | General Counsel | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Peg Horn
BRD | Director/Board Member | 61 | 22-12-14 |
James Meyers
BRD | Director/Board Member | 58 | 19-11-21 |
H. Parker
CHM | Chairman | 68 | 14-06-18 |
Kenneth Hillan
BRD | Director/Board Member | 63 | 20-09-10 |
Robert Carey
BRD | Director/Board Member | 65 | 16-05-31 |
Karen Smith
BRD | Director/Board Member | 56 | 18-06-27 |
Alexander Macrae
CEO | Chief Executive Officer | 61 | 16-05-31 |
John Markels
BRD | Director/Board Member | 58 | 20-02-10 |
Courtney Beers
BRD | Director/Board Member | 54 | 22-12-14 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 207,495,609 | 191,497,330 ( 92.29 %) | 0 | 92.29 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.69% | 104M | |
-2.31% | 103B | |
+0.56% | 95.71B | |
+1.69% | 22.02B | |
-17.37% | 20.9B | |
-9.30% | 17.85B | |
-41.01% | 16.21B | |
-14.85% | 15.52B | |
+3.21% | 13.86B | |
+33.54% | 12.04B |
- Stock Market
- Equities
- SGMO Stock
- Company Sangamo Therapeutics, Inc.